Inhibitors specifically targeting other oncogenic KRAS alleles are currently under active preclinical and early clinical evaluation, including the G12D inhibitors MRTX1133 and BI-KRAS-G12D1-3 that showed promising on-target activity in preclinical models of gastrointestinal tumors including pancreatic cancer [51,55]. This evidence concerns the gene CACNA1A and digestive system neoplasm.